AstraZeneca receives European Commission clearance for Alexion acquisition
The European Commission has cleared AstraZeneca’s proposed acquisition of Alexion Pharmaceuticals for $39bn. This marks an ‘important step’ towards the completion of the acquisition, which was first announced
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.